Metropolis Healthcare IPO
Metropolis Healthcare IPO — date, price band, lot size & details 2019
Metropolis Healthcare listed on 15 Apr 2019 at ₹958, 8.9% above the ₹880 issue price.
Metropolis Healthcare is a Mumbai based diagnostics chain with labs and collection centres in India and six other countries. Its total income was Rs 651.56 crore in FY2018.
Stock price
Metropolis Healthcare is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 14 November.
- Open 03 Apr 2019
- Close 05 Apr 2019
- Allotment 10 Apr 2019
- Refund/credit 11 Apr 2019
- Listing 15 Apr 2019
Issue summary
The terms of the offer, as filed.
| IPO Dates | 3 to 5 Apr, 2019 |
|---|---|
| Price Band | ₹877 – ₹880 |
| Face Value | ₹2 |
| Lot Size | 17 Shares |
| Issue Size | ₹1204.29 Cr |
| Sale Type | OFS only |
| Listing On | BSE, NSE |
| Registrar | MUFG Intime India Private Limited |
| Min Investment | ₹ 14,960 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 17 shares at the ₹880 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 17 | ₹14,960 |
| Retail (max) | 13 | 221 | ₹1,94,480 |
| S-HNI (min) | 14 | 238 | ₹2,09,440 |
| S-HNI (max) | 66 | 1,122 | ₹9,87,360 |
| B-HNI (min) | 67 | 1,139 | ₹10,02,320 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 4
- 01It had 106 clinical laboratories and 1130 collection centres.
- 02Total income rose from Rs 490.63 crore in FY2016 to Rs 651.56 crore in FY2018.
- 03Profit after tax rose from Rs 81.96 crore in FY2016 to Rs 109.75 crore in FY2018.
- 04EBITDA rose from Rs 130.96 crore in FY2016 to Rs 173.38 crore in FY2018.
Risks · 5
- 01Profit after tax grew only slightly, from Rs 107.26 crore in FY2017 to Rs 109.75 crore in FY2018.
- 02Diagnostics faces price competition from chains and hospital labs; total assets were Rs 583.88 crore.
- 03Operating in 7 countries brings currency and regulatory risk.
- 04The whole Rs 1,204.29 crore issue was an offer for sale, so none of it went to the company.
- 05Promoter holding fell from 69.91% before the issue to 57.41% after it.
Three years of numbers
All figures in ₹ crore, as reported in the Metropolis Healthcare offer document.
| Metric | 31 Dec 2018 | 31 Mar 2018 | 31 Mar 2017 | 31 Mar 2016 |
|---|---|---|---|---|
| Assets | 583.88 | 530.34 | 515.16 | 395.92 |
| Total Income | 566.82 | 651.56 | 567.66 | 490.63 |
| Profit After Tax | 88.77 | 109.75 | 107.26 | 81.96 |
| EBITDA | 142.47 | 173.38 | 163.81 | 130.96 |
| Reserves and Surplus | 460.28 | 419.59 | 334.61 | 286.31 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Where the money goes
How the company intends to use the proceeds of the issue.
Information about the usage of proceeds from the Metropolis Healthcare IPO will be updated shortly.
Metropolis Healthcare IPO Anchor Investors
26 anchor investors across 12 fund houses committed ₹530.04 Cr a day before the issue opened.
Anchor investors bid a day before the issue opens and are locked in after allotment, so a book weighted towards domestic mutual funds is generally read as a stronger signal than one filled by short-horizon funds. Browse every anchor investor scheme or fund house we track.
About the company
It had 106 clinical laboratories and 1130 collection centres across seven countries.
In India its labs cover 18 states and 173 cities, for disease monitoring, early detection and screening, and it also supports clinical research.
The IPO was Rs 1,204.29 crore and was entirely an offer for sale at Rs 880, the top of the Rs 877 to Rs 880 band, so the company received no money.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Metropolis Healthcare IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
JM Financial Ltd.
172 issues handledBest listing: Tata Technologies (+140.0%). Weakest: ACME Solar Holdings (-13.1%).
Kotak Mahindra Capital Company Limited
204 issues handledBest listing: Premier Energies (+120.0%). Weakest: Puravankara Projects (-22.5%).
HDFC Bank Limited
34 issues handledBest listing: G R Infraprojects (+105.0%). Weakest: Precision Camshafts (-11.3%).
Goldman Sachs (India) Securities Private Limited
19 issues handledBest listing: Bajaj Housing Finance (+114.3%). Weakest: Paytm (-9.3%).
Credit Suisse Securities (India) Pvt. Ltd
20 issues handledBest listing: Zomato (+52.6%). Weakest: Sterling & Wilson Solar (-9.5%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Metropolis Healthcare?
The current Grey Market Premium is ₹47.5, or 5% over the issue price.
What is the Metropolis Healthcare IPO price band?
₹877 to ₹880, on a face value of ₹2.
When is the allotment?
The basis of allotment is 10 April 2019, with listing on 15 April 2019.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — MUFG Intime India Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
